The scientific basis of medical therapy of acute pancreatitis. Could it work, and is there a role for lexipafant?
For a 30-year period beginning in 1958, the general basis of medical therapy of acute pancreatitis had as its focus the provision of supplementary antiprotease therapy usually given intravenously. This concept was based on the belief that the body's natural antiprotease defense mechanism, which relies heavily on alpha 2-macroglobulin, together with alpha 1-antiprotease (alpha 1-antitrypsin), was inadequate to cope with the vast enzyme release that occurred with the onset of the more severe forms of the disease. This article examines recent studies and emerging theories on the medical therapy of acute pancreatitis.
Imrie
C W
CW
Glasgow Royal Infirmary, Scotland, United Kingdom.
McKay
C J
CJ
D000208:Acute Disease; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010195:Pancreatitis / Q000188:drug therapy*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic
D007093:Imidazoles; D010972:Platelet Activating Factor; D007930:Leucine; C103289:lexipafant